10x Genomics launched a next-generation Chromium Flex assay that expands plate-based multiplexing to 384 samples and promises throughput up to hundreds of millions of cells per week. Early-access users report dramatic gains in scalability and per-sample cost reductions enabled by an updated Flex chemistry and an automation-compatible workflow. The product targets translational and high-throughput research—CRISPR screens, large cohorts and FFPE studies—and aims to lower barriers for single-cell adoption in pharma and large academic consortia. Vendors and service labs that handle large sample loads are likely to update processing pipelines and automation to capitalize on the increased per-chip capacity. Technical customers note the additional sample prep step for the Flex kit but highlight the step-change in chip economics and cell capture numbers. If adoption scales, expect downstream impacts on sequencing demand, data storage and single-cell analytics ecosystems.